Andrew Pearlman, MD
Insurance Plans Accepted:
Dr. Pearlman is a Board Certified Radiation Oncologist, with vast experience in the treatment of all cancers, including head & neck cancers, gastrointestinal cancers, with specialization in urogenital cancers, such as prostate, bladder and testicular cancers. He has significant experience in the integration and development of Radiation Oncology technology, including Stereotactic Radiosurgery (SRS) for brain and central nervous system tumors.
Education & Training:
BS: Massachusetts Institute of Technology (MIT), Cambridge, MA (Nuclear Engineering)
MD: Albert Einstein College of Medicine, NY
Residency: Montefiore Medical Center, Bronx, NY (Internal Medicine)
Fellowship: The Johns Hopkins Hospital, Baltimore, MD (Radiation Oncology)
Internal Medicine (American Board of Internal Medicine)
Radiation Oncology (American Board of Radiology)
College of Physicians
American Medical Association
American Society of Clinical Oncology
Research & Publications
Pearlman A, Shaw E: Spinal Cord Tumors (Chapter 20). In: Gunderson & Tepper (eds): Clinical Radiation Oncology, 1st edition. New York, Churchill Livingstone, 2000.
Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Pearlman AD, et al. A phase IB study to evaluate repeated daily intravenous doses of RSR13 administered to cancer patients receiving concurrent radiation therapy. Int J Radiat Oncol Biol Phys 1997; 39(25):330.
Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Pearlman A, Ruffer J, Priet R. Phase I toxicity, pharmacodynamic (PD), and pharmacokinetic (PK) results with RSR13 in newly diagnosed glioblastoma (GBM). Proceedings of New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium, Baltimore, MD, 1997.
Kavanagh BD, Pearlman AD, Schmidt-Ullrich RK, Shaw EG, Dusenbery KE, Gerber MJ. Clinical experience with RSR13, a radiation-enhancing hemoglobin modifier, for recurrent and metastatic brain tumors. Presented at 10th International Conference on Chemical Modifiers of Cancer Treatment, January, 1998.
Roberts JA, Brunetto VL, Keys HM, Zaino R, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG. A phase III randomized study of surgery vs. surgery plus adjunctive radiation therapy in intermediate risk endometrial adenocarcinoma. Proceedings of Society of Gynecologic Oncologists 29th Annual Meeting, 1998, p. 70.
Shaw E, Scott C, Stea B, Suh J, Kadish S, Hackman J, Pearlman A, Gerber M, Murray K, Gaspar L, Mehta M, Curran W. Survival improvement with RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison to the Radiation Therapy Oncology Group recursive partitioning analysis brain metastases database. Proceedings of ASCO 36th Annual Meeting, 2000, p. 159a.
Shaw E, Scott C, Stea B, Suh J, Kadish S, Hackman J, Pearlman A, Gerber M, Murray K, Gaspar L, Mehta M, Curran W. RSR13 plus cranial radiation therapy improves survival in patients with brain metastases compared to the RTOG recursive partitioning analysis brain metastases database: Update of a phase II trial. Proceedings of the 42nd Annual ASTRO Meeting, 2000, p. 203. (Int J Radiat Oncol Biol Phys 2000; 48(3S):203).
Shaw E, Scott C, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 2003; 21(12): 2364-71.
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(3): 744 –51.
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, et al. A phase III Trial of Surgery With or Without Adjunctive External Pelvic Radiation Therapy in Intermediate-Risk Endometrial Adenocarcinoma: A Gynecologic Oncology Group Study. Obstet Gynecol Surv. 2004; 59(7): 516–518.